Chart: OIG's Planned Pharmaceutical-Related Investigations
You may also be interested in...
HHS' Office of Inspector General will examine how FDA handles the growing number of clinical trials being conducted overseas
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials